三磷酸腺苷-肿瘤体外药敏检测在晚期卵巢上皮癌化疗中的成本-效果评价  

Cost-effectiveness of adenosine triphosphate-tumor chemosensitivity assay in advanced epithelial ovarian cancer chemotherapy

作　　者：常青云[1] 吴令英[2] 李晓光[2] 田海梅[1] 李茉[1] 李艳芬[1] 赵丹[2] 王小兵[1] 宋培培[1] 刘静[1] 付超[3] 刘珊[1] 刘毅[1] 张伟 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院生物检测中心,北京100021 [2]中国医学科学院北京协和医学院肿瘤医院妇瘤科,北京100021 [3]中国医学科学院北京协和医学院肿瘤医院检验科,北京100021

出　　处：《癌症进展》2011年第2期191-195,216,共6页Oncology Progress

基　　金：科技部中小企业技术创新基金(项目编号:03c26211100757)

摘　　要：目的评价三磷酸腺苷—肿瘤体外药敏检测(adenosine triphosphate-tumor chemosensitivity assay,ATP-TCA)在晚期卵巢上皮癌化疗中的应用价值,以及对该技术应用的成本-效果进行评价。方法回顾性分析158例在我院例行ATP-TCA检测的晚期卵巢上皮癌病例,其中原发67例,复发91例,为ATP-TCA检测治疗组。根据分期和年龄选取同期153例常规治疗的晚期卵巢上皮癌病例作为对照组;采用半年化疗的临床近期有效率对患者疗效进行评价,并对术后半年内的治疗方案进行统计和费用计算;采用"成本-效果分析(CEA)"法评价ATP-TCA检测技术应用的卫生经济学价值。结果 ATP-TCA检测治疗组与对照组临床近期有效率分别为58.2%和46.4%,两组差异显著(P=0.041);原发病例中,ATP-TCA检测治疗组与对照组临床近期有效率分别为77.6%和71.4%,两组差异无统计学意义(P=0.429);复发病例中,ATP-TCA检测治疗组与对照组临床近期有效率分别为44.0%和28.9%,两组差异显著(P=0.045);ATP-TCA检测治疗组平均费用50293.42元人民币,对照组治疗平均化疗药物费用46495.10元人民币,两组间无显著差异(P=0.210)。成本-效果分析结果表明ATP-TCA检测治疗组相对于对照组的边际成本ΔC/ΔE为321.89,远小于对照组C/E值1002.00。结论 ATP-TCA检测技术应用在晚期复发性卵巢上皮癌治疗中提高了临床近期疗效;该技术应用的成本-效果明显。Objective To assess the value of adenosine triphosphate-tumor ehemosensi^ivity assay （ ATP-TCA ） in advanced epithelial ovarian cancer chemotherapy. Methods In this retrospective ease-control study, 158 patients underwent ATP-TCA （67 primary and 91 recurrent cases）. The short-term effectiveness of ehemotherapy were studied within six months after the surgery therapy and the cost-effectiveness of ATP-TCA was calculated. Results The short-term effective rate was 58.2% and 46. 4% in the ATP-TCA group and the control group, respectively （P = 0. 041 ）. In the relapse cases, the short-term effectiveness rate in ATP-TCA.group and control group were 44. 0% and 28.9% , respectively （ P = 0. 045 ）. The average cost of the ATP-TCA group and the control group was 50, 293.42CNY and 46, 495. 10CNY, respeclively （P = 0. 210）. The marginal cost （AC/AE） of ATP-TCA group was 321.89, which was for lower than the C/E ratio of the control group （ 1002. 00）. Conclusion ATP-TCA can improve the shortqerm effectiveness of advance epithelial ovarian cancer chemotherapy with lower cost.

关 键 词：卵巢癌 三磷酸腺苷-肿瘤体外药敏试验 成本-效果分析 

分 类 号：R737.31[医药卫生—肿瘤]